Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: A case series

Gabriella D'Ettorre, G. Barbarini, F. Corti, M. Gobber, C. Pastecchia, G. L. Ricci, M. Siciliano, B. E. Annicchiarico, V. Vullo

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6±14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4±4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0±3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2±5.9 and 6.8±4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7±0.6 months and 10.0±2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.

Original languageEnglish
Pages (from-to)551-554
Number of pages4
JournalEuropean Review for Medical and Pharmacological Sciences
Volume14
Issue number6
Publication statusPublished - Jun 2010

Keywords

  • Entecavir
  • HBV infection
  • Seroconversion

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: A case series'. Together they form a unique fingerprint.

Cite this